Paper Details

  1. Home
  2. Paper Details

Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.

Author: DiphokoThabo, EssexMax, GaseitsiweSimani, KasvosveIshmael, MakhemaJoseph, MarlinkRichard, MoyoSikhulile, MusondaRosemary, NovitskyVladimir, OkatchHarriet, WainbergMark

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the prevalence of HIV-1 drug resistance mutations (DRMs) to rilpivirine (RPV) and etravirine (ETR) in Botswana. High prevalence of RPV and ETR DRMs was found even though these drugs have not been used in Botswana. This highlights the importance of genotyping patients with prior exposure to nevirapine or efavirenz before prescribing RPV- or ETR-containing therapies.
Paper Details　
Original Abstract of the Article :
Rilpivirine (RPV) and Etravirine (ETR) are approved second-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV treatment. There is a cross-resistance HIV mutation profile between first- and second-generation NNRTI drugs. We determined the prevalence of HIV-1 drug resistance m...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079649/

データ提供：米国国立医学図書館（NLM）

Facing HIV Resistance: A Challenge in Botswana

The journey towards HIV treatment is a challenging one, my friend. Resistance to HIV medication is a formidable obstacle, requiring a careful approach and a watchful eye. This study examines the prevalence of resistance to specific HIV medications in Botswana, a country facing a significant HIV burden. The researchers focused on understanding the patterns of resistance to rilpivirine and etravirine, two important second-generation medications, in patients who had previously failed other HIV treatments.

A Shifting Landscape: Resistance Patterns and Implications

The study found that resistance to rilpivirine and etravirine was common in patients who had previously failed nevirapine or efavirenz-based treatments. This highlights the importance of careful monitoring and genetic testing before prescribing second-generation medications to individuals who have already experienced resistance to other drugs. It's like navigating a shifting desert landscape, where a familiar route may lead to unexpected challenges.

Preventing Resistance: A Collaborative Effort

This study emphasizes the need for proactive measures to prevent and manage HIV resistance. Regular monitoring, genetic testing, and personalized treatment plans are crucial for ensuring the effectiveness of HIV therapies. By working together, healthcare providers and patients can effectively navigate this complex terrain and achieve the best possible outcomes.

Dr.Camel's Conclusion

HIV resistance is a complex and dynamic challenge. This study sheds light on the prevalence of resistance to specific medications in Botswana, highlighting the need for careful monitoring and individualized treatment strategies. By understanding the patterns of resistance and working collaboratively, we can improve the effectiveness of HIV treatments and create a more hopeful future for patients.

Date :
  1. Date Completed 2019-07-16
  2. Date Revised 2020-12-09
Further Info :

Pubmed ID

29732907

DOI: Digital Object Identifier

PMC6079649

Related Literature

Article Analysis
・Effects of etravirine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.